Compare Novo Nordisk A/S (NVO) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sprott Uranium Miners ETF — how do they compare? Novo Nordisk A/S trades at $46.39 (market cap $207.85B), while Sprott Uranium Miners ETF trades at $55.4. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Sprott Uranium Miners ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| NVO | URNM | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $83.99 |
52-Week Low | $35.29 | $44.14 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
URNM trades at $55.39, up 1.45% today, with a bullish technical signal supported by moving averages. Recent news highlights nuclear energy's role in meeting AI power demand, with government funding and international deals creating positive momentum. The ETF focuses on uranium miners, offering concentrated exposure to the nuclear supply chain.
The outlook for URNM is positive due to growing nuclear energy demand from AI data centers and government support, though risks include uranium price volatility and concentrated miner exposure. Wall Street sentiment is mixed, with some analysts favoring pure-miner funds while others caution on valuation gaps versus spot prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
